(no author information available yet)
No abstract text is available yet for this article.
2022: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
(no author information available yet)
No abstract text is available yet for this article.
2022: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Zahra Ghaemi, Bahram M Soltani, Seyed Javad Mowla
BACKGROUND: ErbB/PI3K signaling is widely recognized as a critical modulator of malignancy and miRNAs have been found to play a crucial role in the regulation of this pathway. OBJECTIVE: This study aimed to identify novel miRNAs related to the ErbBs loci and investigate the functional effects of these miRNAs on ErbB/PI3K signaling in cancer progression. MATERIALS AND METHODS: Bioinformatics tools and RNA-seq data were used to discover novel miRNAs in breast and colon cancer cells...
2022: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Haluk Damgacioglu, Yueh-Yun Lin, Ana Patricia Ortiz, Chi-Fang Wu, Zahed Shahmoradi, Shiang Shiuan Shyu, Ruosha Li, Alan G Nyitray, Keith Sigel, Gary M Clifford, Naomi Jay, Vivian Colon Lopez, Gregory M Barnell, Elizabeth Y Chiao, Elizabeth A Stier, Karen J Ortiz-Ortiz, Jeslie M Ramos-Cartagena, Kalyani Sonawane, Ashish A Deshmukh
PURPOSE: Squamous cell carcinoma of the anus (SCCA) incidence and mortality rates are rising in the United States. Understanding state-level incidence and mortality patterns and associations with smoking and AIDS prevalence (key risk factors) could help unravel disparities and provide etiologic clues. METHODS: Using the US Cancer Statistics and the National Center for Health Statistics data sets, we estimated state-level SCCA incidence and mortality rates. Rate ratios (RRs) were calculated to compare incidence and mortality in 2014-2018 versus 2001-2005...
November 28, 2022: Journal of Clinical Oncology
Jean de la Rosette, Jose Dominguez-Escrig, Kai Zhang, Jeremy Teoh, Eric Barret, Juan Casanova Ramon-Borja, Gordon Muir, Julia Bohr, Theo de Reijke, Chi-Fai Ng, Chi-Ho Leung, Rafael Sanchez-Salas, Pilar Laguna
PURPOSE: Our goal was to evaluate the effect of focal vs extended irreversible electroporation on side effects, patient-reported quality of life, and early oncologic control for localized low-intermediate risk prostate cancer patients. MATERIALS AND METHODS: Men with localized low-intermediate risk prostate cancer were randomized to receive focal or extended irreversible electroporation ablation. Quality of life was measured by International Index of Erectile Function, Expanded Prostate Cancer Index Composite questionnaire, and International Prostate Symptom Score...
November 28, 2022: Journal of Urology
Ameen Z Alherabi, Rehab F Simsim, Suha H Alsayed, Ahmad S Alharthi, Osama Marglani
BACKGROUND Nasopharyngeal carcinoma (NPC) is a rare malignant tumor that arises from the mucosal lining epithelium of the nasopharynx, most commonly at the lateral nasopharyngeal recess or fossa of Rosenmüller. According to global age-standardized incidence rates (ASIRs), in 2018 the incidence rate of nasopharyngeal carcinoma varied from 2.1 to 0.4 per 100 000 in Asia and Europe, respectively. The number of deaths exceeded 50 000. It is one of the few head and neck tumors prone to distant metastasis, most commonly to bones, lung, and liver...
November 28, 2022: American Journal of Case Reports
Yanjia Zhuang, Xiaogang Pang, Yuchen Qi, Tianshu Zhang, Guimao Cao, Heming Xue, Yifan Xu, Shuoxin Xie, Yifan Liu, Yinuo Wang, Yunxiao Li, Ying Xiong, Yuanyuan Li, Hui Shen
[This corrects the article DOI: 10.3389/fonc.2022.939636.].
2022: Frontiers in Oncology
Amber L Chang, Hyunjee V Kwak, Minggui Pan, Peter D Peng, Lee J Morse, C K Chang
INTRODUCTION: The purpose of this study is to analyze the impact of a virtual multidisciplinary sarcoma case conference (VMSCC) on the outcomes of dermatofibrosarcoma protuberans (DFSP). METHODS: We compared margin status after surgery and disease-free survival (DFS) on two cohorts of patients with DFSP, one diagnosed from 2010 to 2015 and one from 2016 to 2020 (before and after virtual multidisciplinary sarcoma case conference (VMSCC) within Kaiser Permanente Northern California (KPNC), using Kaplan-Meier curves and Cox proportional hazard regression models...
November 28, 2022: American Surgeon
Yahiya Y Syed
Futibatinib (Lytgobi® ) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1-4 that is being developed by Taiho Oncology and Taiho Pharmaceutical for the treatment of cancers, including cholangiocarcinoma, breast cancer, gastric cancer, urothelial cancer, oesophageal cancer and non-small cell lung cancer. Futibatinib was approved in the USA on 30 September 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements...
November 28, 2022: Drugs
Jyoti Malhotra, Edward S Kim
PURPOSE OF REVIEW: Oncolytic viruses (OVs) exert their antitumor effect through selective killing of cancer cells and induction of host anti-tumor immunity. This review aims to summarize the recent and current trials with OVs for the treatment of lung cancer. RECENT FINDINGS: Several OVs have been developed for the treatment of lung cancer including adenovirus, coxsackievirus B3, reovirus, and vaccinia virus and trials have demonstrated a safe toxicity profile. Early-phase trials in lung cancer with OVs have reported antiviral immune responses and evidence of clinical benefit...
November 28, 2022: Current Oncology Reports
Rachel E Goodman, Morgan Lamberg, Kate Wilcox, Anum Minhas, Rachel Bond, Eric H Yang, Negeen Shahandeh, Sherry-Ann Brown
PURPOSE OF REVIEW: Cardiovascular disease (CVD) is the leading cause of mortality in adult women in the USA, yet CVD is underrecognized in women. Disparities in care are further pronounced in women of racial/ethnic minority backgrounds. In this review, we discuss the role of social media (SoMe) as a tool to (i) promote women's cardiovascular (CV) health and (ii) address and potentially reduce gaps in care, particularly in general cardiology (targeting atherosclerotic cardiovascular disease), cardio-oncology, and cardio-obstetrics...
November 28, 2022: Current Atherosclerosis Reports
Nicole L Stout, Ralph Utzman, Hannah Hazard Jenkins, Megan Burkart, Anne K Swisher
BACKGROUND: The prospective surveillance model (PSM) is an evidence-based rehabilitation care delivery model that facilitates functional screening and intervention for individuals undergoing cancer treatment. While PSM is empirically validated and feasible in practice, implementation into cancer care delivery has languished. The purpose of this manuscript is to characterize the barriers and facilitators to implementing PSM in a breast cancer center and to share policy and process outcomes that have sustained the model in practice...
November 28, 2022: Journal of Cancer Survivorship: Research and Practice
Chi-Hyun Ahn, Kyu-Young Oh, Bohwan Jin, Won Woo Lee, Jihoon Kim, Hyun-Ji Kim, Dong-Guk Park, Neeti Swarup, Kunal Chawla, Mi Heon Ryu, Uk-Kyu Kim, Su-Jung Choi, Hye-Jung Yoon, Seong-Doo Hong, Ji-Ae Shin, Sung-Dae Cho
PURPOSE: PD-L1 is an immune checkpoint protein that allows cells to evade T-cell-mediated immune responses. Herein, we uncover a tumor-intrinsic mechanism of PD-L1 that is responsible for the progression and aggressiveness of HNC and reveal that the extracts of a brown alga can target the tumor-intrinsic signaling pathway of PD-L1. METHODS: The biological functions of PD-L1 in the proliferation and aggressiveness of HNC cells in vitro were examined by metabolic activity, clonogenic, tumorigenicity, wound healing, migration, and invasion assays...
November 28, 2022: Cellular Oncology (Dordrecht)
Lars Michel, Matthias Totzeck, Tienush Rassaf
The continuous improvement in cancer treatment leads to a growing number of long-term survivors. Arguably, the treatment of cardiovascular side effects from cancer therapy is therefore of major importance for the morbidity and mortality affected patients. The 2022 ESC guidelines on cardio-oncology of the European Society of Cardiology (ESC) aim to improve the treatment of affected patients across the entire continuum of therapy and in the long term by establishing standardized procedures for prevention, diagnostics, and treatment of cardiovascular side effects...
November 28, 2022: Herz
Klaus-Peter Dieckmann, Silke Tribius, Mathias Angerer, Andrea Salzbrunn, Kathrein von Kopylow, Martin Mollenhauer, Christian Wülfing
PURPOSE: Germ cell neoplasia in situ (GCNis), the precursor of adult testicular germ cell tumours (GCTs), is found in 5-6% of contralateral testicles in patients with testicular GCT and in the tumour-surrounding tissue of > 90% of testes undergoing testis-sparing surgery (TSS) for GCT. Local radiotherapy to the testis with 18-20 Gy eradicates GCNis while preserving Leydig cells. The frequency of treatment failures is so far unknown. METHODS: A 22-year-old patient with right-sided seminoma clinical stage I and contralateral GCNis received radiotherapy with 18 Gy to his left testicle...
November 28, 2022: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Benoît Allignet, Pierre Pradat, Françoise Mornex, Floriane Izarn, Agnès Rode, Jean-Yves Mabrut, Kayvan Mohkam, Philippe Merle
BACKGROUND AND OBJECTIVE: Transarterial chemoembolization (TACE) is the gold standard treatment in intermediate hepatocellular carcinoma (HCC), but long-term disease control rates remain low. Herein, we compared results of TACE followed by hypofractionated radiotherapy (TACE-hRT) to surgical resection (SR) in early single or paucinodular intrahepatic HCC. METHODS: Between June 2004 and November 2016, data on 160 consecutive patients with Barcelona Clinic Liver Cancer (BCLC) stage A Child-Pugh A HCC treated with SR or TACE-hRT in our expert center were retrospectively reviewed...
November 28, 2022: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Jordi Remon, Lizza E L Hendriks, Giannis Mountzios, Rosario García-Campelo, Stephanie P L Saw, Dipesh Uprety, Gonzalo Recondo, Guillermo Villacampa, Martin Reck
Targeted therapies have revolutionized the treatment and improved the outcome for oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have become available. For MET-dysregulated NSCLC (especially MET exon 14 skipping mutations and MET-amplifications, which is one of the most common bypass mechanisms of resistance in oncogene-addicted NSCLC), several anti-MET-targeted therapies have been approved recently (MET exon 14 skipping mutation) and multiple others are in development. In this narrative review, we summarize the role of MET as an oncogenic driver in NSCLC, discuss the different testing methods for exon 14 skipping mutations, gene amplification, and protein overexpression, and review the existing data and ongoing clinical trials regarding targeted therapies in MET-altered NSCLC...
October 29, 2022: Journal of Thoracic Oncology
Evan E Gross, Mingjia Li, Ming Yin, Delaney Orcutt, Duncan Hussey, Elliot Trott, Sarah K Holt, Erin R Dwyer, Joel Kramer, Kaylee Oliva, John L Gore, George R Schade, Daniel W Lin, Scott S Tykodi, Evan T Hall, John A Thompson, Anish Parikh, Yuanquan Yang, Katharine A Collier, Abdul Miah, Sherry Mori-Vogt, Megan Hinkley, Amir Mortazavi, Paul Monk, Edmund Folefac, Steven K Clinton, Sarah P Psutka
BACKGROUND: Cytoreductive nephrectomy (CN) for the treatment of metastatic renal cell carcinoma (mRCC) was called into question following the publication of the CARMENA trial. While previous retrospective studies have supported CN alongside targeted therapies, there is minimal research establishing its role in conjunction with immune checkpoint inhibitor (ICI) therapy. OBJECTIVE: To evaluate the association between CN and oncological outcomes in patients with mRCC treated with immunotherapy...
January 2023: Urologic Oncology
Eline H Huele, Paul W Veenboer, Frank J Wessels, Trudy N Jonges, Richard P Meijer
BACKGROUND: Initial tumour staging in bladder cancer mainly relies on the histo-pathological outcome of the transurethral bladder tumour resection (TURBT) and imaging by means of a CT-scan (CT-intravenous urography; CT-IVU). The reported risk of understaging varies from 24-50%. To further improve the the evaluation of depth of invasion of the bladder tumour the application of magnetic resonance imaging (MRI) may be useful. To substantiate the additional value of this imaging modality the present observational study was designed...
January 2023: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.